 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced that the U.S. Food and Drug Administration FDA has granted orphan-drug designation ODD to ALLO-715 for the treatment of multiple myeloma. 